Veracyte Closes $40 Million Private Placement Transaction

Veracyte Closes $40 Million Private Placement Transaction

Molecular diagnostics company Veracyte, Inc., which is developing a genomic test to help improve diagnosis of Idiopathic Pulmonary Fibrosis (IPF) has announced the establishment of a definitive agreement for the trade of common stocks, worth $40 million, in a private placement. Investors acquired 4,907,975 shares of common stock at a purchase price of…

New Veracyte/GE Partnership May Lead To Improved IPF Diagnosis

The molecular diagnostic company Veracyte, Inc. and the multinational conglomerate corporation GE have established a research partnership focused on developing novel solutions able to improve the diagnosis of diseases such as Idiopathic pulmonary fibrosis (IPF). The companies did not disclose the financial terms of the collaboration. Veracyte will work…

Pacific Therapeutics gets US Patent Office Notice Of Allowability for Pulmonary Fibrosis treatment

Pacific Therapeutics Ltd., a clinical stage pharmaceutical company that leads programs focused on erectile dysfunction and diseases of excessive scarring (fibrosis), announced that the US Patent Office (PO) has released a Notice Of Allowability for the Company’s patent application, Compositions and Methods for the treatment of fibroproliferative conditions. Doug Unwin,…

Liposomes Loaded With Anti-fibrotic Drugs Offer Promising Idiopathic Pulmonary Fibrosis Treatment Approach

In a recent study entitled “Efficient Delivery to Human Lung Fibroblasts (WI-38) of Pirfenidone Incorporated into Liposomes Modified with Truncated Basic Fibroblast Growth Factor and Its Inhibitory Effect on Collagen Synthesis in Idiopathic Pulmonary Fibrosis,” researchers highlighted a promising, novel treatment for idiopathic pulmonary fibrosis that…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums